Streetbeat News

Stock Prices

BLRX

BioLineRx disclosed promising data from a Phase 2 clinical trial evaluating Motixafortide in first-line pancreatic cancer at the ASCO 2024 Annual Meeting. The study showed significant increases in CD8+ T-cell density and high rates of partial response and disease control among patients.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 11:03 am

BYDDF

BYDDY

BYD Co., Ltd. (OTC:BYDDF) (OTC:BYDDY) is set to unveil its fifth-generation DM hybrid technology, which promises a vehicle range of up to 2,000 kilometers. The new technology will be launched on May 28, and the company plans to transition to this model gradually. BYD's shares closed lower by 2.82% to $27.21 on Thursday.

Portfolio Pulse from Nabaparna Bhattacharya

May 24, 2024 | 11:00 am

GOOG

GOOGL

Elon Musk criticized Google's AI-powered search feature for its poor performance, using his Grok AI chatbot to mock Google's suggestion that users should eat rocks daily. This incident adds to the scrutiny Google’s AI has been facing, including previous inaccuracies and controversial descriptions.

Portfolio Pulse from Rounak Jain

May 24, 2024 | 11:00 am

BKE

Buckle (NYSE:BKE) reported Q1 earnings per share (EPS) of $0.69, missing the analyst consensus estimate of $0.74 by 6.76%. This represents a 19.77% decrease from the same period last year. Quarterly sales were $262.48 million, also missing the estimate of $263.64 million by 0.44%, and showing a 7.20% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 10:53 am

TSLA

Tesla Inc. (NASDAQ:TSLA) has significantly reduced the production of its Model Y SUV at its Shanghai gigafactory due to waning demand in China. The production cut, which began in March, is a response to a fierce price war among electric vehicle manufacturers and an economic slowdown in China. The Shanghai plant plans to reduce Model Y output by at least 20% from March to June. Tesla's market share in China's electric and plug-in hybrid market has dropped, and the company sold 62,617 made-in-China EVs in April, down 18% year-over-year.

Portfolio Pulse from Anan Ashraf

May 24, 2024 | 10:48 am

NVO

Novo Nordisk's Ozempic has shown promising results in a late-stage trial, slowing the worsening of kidney dysfunction and lowering the risk of kidney failure, heart problems, stroke, and death in type 2 diabetes patients.

Portfolio Pulse from Charles Gross

May 24, 2024 | 10:36 am

STLA

TSLA

Jeep's all-electric Wagoneer S SUV outperforms Tesla's Model Y Performance in acceleration tests but lags behind the Model X Plaid. The Wagoneer S, expected to be available in late 2024, will start at around $80,000, while the Model Y Performance is priced at $51,490.

Portfolio Pulse from Anan Ashraf

May 24, 2024 | 10:29 am

FEPI

MU

NLST

PSI

Micron Technology Inc (NASDAQ:MU) has been ordered to pay $445 million in damages to Netlist Inc (OTC:NLST) for patent infringement. The jury found Micron's infringement to be willful, potentially increasing the damages. This follows a previous $303 million verdict Netlist secured against Samsung Electronics Co Ltd (OTC:SSNLF). Micron's stock has gained over 89% in the last 12 months, and investors can gain exposure via Invesco Semiconductors ETF (NYSE:PSI) and REX FANG & Innovation Equity Premium Income ETF (NASDAQ:FEPI).

Portfolio Pulse from Shivani Kumaresan

May 24, 2024 | 10:23 am

MCD

YUM

McDonald's (NYSE:MCD) and Yum! Brands' (NYSE:YUM) KFC are facing significant sales declines in Asia, the Middle East, and parts of Europe due to boycotts linked to the Israel-Gaza conflict. The boycotts are particularly severe in Muslim-majority countries, impacting McDonald's and KFC outlets in Egypt, Jordan, Morocco, Indonesia, Malaysia, and Pakistan.

Portfolio Pulse from Benzinga Neuro

May 24, 2024 | 10:10 am

EXAS

Exact Sciences demonstrates leadership in early cancer diagnosis with multiple data presentations at the American Society of Clinical Oncology Annual Meeting. Key highlights include the predictive and prognostic value of the Oncotype DX Breast Recurrence Score® test and data on multi-cancer early detection (MCED) and Cologuard® test adherence.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 10:06 am